| |
 |
September 18, 2008
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has made a major innovation in its Radiant Energy Vacuum (“REV”) pharmaceutical dehydration technology to allow for a significant reduction in the moisture content of dried vaccine products.
The new technology, called freezeREV, provides high-speed live pharmaceutical dehydration with the potential for lower energy and processing costs than conventional technology being used by the industry today. > Read more
Related Reading
Overcoming the Cold-Chain Hurdle for Vaccines
The World Health Organization (www.who.org) specifies that, in order to ensure adequate potency, most liquid vaccines are to be stored and transported at temperatures between 2˚C and 8˚C from the time of manufacture to their use. This is an expensive and complicated process in developed countries, and it can be nearly impossible in developing countries where vaccination clinics are located outside urban centres.
A study outlined in the East African Medical Journal, 2000, illustrated the typical condition of the cold chain system in a vaccine administration center: "33% did not maintain proper temperature records; 11.7% had thermometer readings outside the recommended range; and 6.2% had no functional thermometers. Overall, the study indicated weaknesses in the cold chain system of the country, which could compromise the potency of vaccines and quality of immunization services."
EnWave is working to develop its bioREV and freezeREV technologies in order to produce room-temperature stable vaccines and antibodies that can be shipped and stored without the need for refrigeration.
> EnWave Homepage
> Latest News
> Investor Information
> Contact Us |
 |
|
